The Tiny Biotech That Just Embarrassed a Billion-Dollar Drug

That's like upgrading from a monthly car payment to paying once a year. Same car, way less hassle.

Wall Street's Reaction Was Swift

Oruka shares (NASDAQ: ORKA) climbed sharply after the data dropped, reaching the low-to-mid $80s by the end of April 27, with intraday highs touching $91.00. Trading volume spiked to roughly 1.3 million shares as momentum traders and biotech specialists piled in.

The analyst community largely validated the enthusiasm. Guggenheim maintained its Buy rating, ultimately raising its price target to $200, the most bullish call on the street. Leerink Partners sat at $86 (Outperform), Wedbush at $85, and UBS at $75. The consensus across 10 firms: Moderate Buy, with an average target of $78.90 that now looks conservative given where shares landed.

Oruka wasted no time capitalizing. Shortly after the data release, the company announced a $500 million stock offering (with a $75 million overallotment option) to fund further development. When the market hands you a premium valuation, you take the money.

The Goliath in the Room

To appreciate what Oruka is really up against, you need to understand how massive the IL-23 psoriasis market has become. Skyrizi generated $11.7 billion in 2024, with strong growth continuing into 2025. That kind of growth trajectory is rare for any drug, let alone one competing in a crowded immunology space.

AbbVie projects that Skyrizi and its partner drug Rinvoq will combine for over $31 billion in 2027. The company has more than a million patient-years of real-world exposure data in the U.S. alone. It has approvals across psoriasis, psoriatic arthritis, and inflammatory bowel disease. It has the kind of commercial infrastructure that takes decades to build.

Oruka, by contrast, has 63 patients and zero approved products, though the recent stock offering will significantly bolster its cash position. This is David vs. Goliath, and David just landed a very clean punch.

Why "Better Data" Isn't Enough (Yet)

Before anyone starts planning Skyrizi's funeral, some important caveats. Phase 2 trials are small. They're designed to find the right dose and get early efficacy signals, not to prove a drug works definitively. The EVERLAST-A trial enrolled about 84 patients total across active and placebo arms. Cross-trial comparisons (stacking ORKA-001's numbers against Skyrizi's from different studies) are notoriously unreliable because patient populations, disease severity, and trial designs can vary enormously.

Oruka still needs to run larger Phase 2b and Phase 3 studies. The EVERLAST-B trial is already underway, which is encouraging. But durability data (how long patients stay clear after dosing stops or between annual doses) remains the billion-dollar question. Showing great results at Week 16 is one thing; proving that a single injection keeps working for 12 months is a much harder ask.

The safety profile looked clean so far, with adverse events comparable to placebo and consistent with other IL-23 drugs. That's reassuring but unsurprising at this stage. Real safety signals often emerge in larger, longer trials.

A Crowded Arena Getting More Interesting

Oruka isn't the only challenger circling Skyrizi. The IL-23 inhibitor landscape includes J&J's Tremfya (dosed every 8 weeks), Sun Pharma's Ilumya (every 12 weeks), and Eli Lilly's recently approved Omvoh. On the horizon, oral IL-23 inhibitors like J&J's icotrokinra (ICOTYDE), which received FDA approval in March 2026, could reshape the market entirely by eliminating injections altogether.

But none of those competitors offer what Oruka is dangling: potentially Skyrizi-level (or better) efficacy with dramatically less frequent dosing. In a world where patient adherence is one of the biggest challenges in chronic disease management, convenience matters. A lot.

For a company that didn't exist two years ago, Oruka just served notice to the entire dermatology market. The data is early, the road is long, and AbbVie has billions of reasons to fight back. But for one day in late April, the little biotech that could looked like it might actually do it.